Categories
- Active Surveillance
- Announcements
- Ask Dr. Barken
- Biomarker
- Biopsy
- Bone Metastases
- Brachytherapy
- Cancer Stem Cells
- Castration Resistant Prostate Cancer
- CETC
- Checklist
- Choline 11 PET Scan
- Clinical Trials
- Coaching
- Color Doppler Trans-Rectal Ultrasound
- Cryo Immunotherapy
- Cryoablation
- CTC
- Decision Making
- Diagnosis
- Exosome
- Ferumoxytol
- Focal Therapy
- Genome
- HIFU
- High Intensity Foucused Ultrasound
- Hormonal Blockade
- Hormone Refractory Disease
- Imaging
- Immune Therapy
- Intermittent Hormonal Blockade
- Journal Club
- Laser
- LIfe Style
- Liquid Biopsy
- Lymph Nodes
- Markers
- Metastatic Disease
- Metastatic Prostate Cancer Disease
- MRI
- MRI Guided Focal
- Multi Parameteric MRI
- Nutrition
- PCREF Support Group Meeting
- PET scans
- Photodynamic Therapy
- Prevention
- Prognosis
- Prostate Cancer
- PSA
- Radiation Therapy
- Radiation treatment
- Radical Prostatectomy
- Sequential Hormonal Blockade
- Sexual Dysfunction
- Support for Prosatate Cancer
- Survival prostate cancer
- Testosterone
- Theranostics
- Treatments for Prostate Cancer
- Tumor Spheres
- Uncategorized
- Vaccine
Category Archives: PSA
Ten Things Physicians and Patients Should Question.
The “Chose Wisely” Israel Barken M.D., discusses the Choose Wisely program. The program created by cooperation between the American Board of Internal Medicine and the American Urological Association.
Percentage Involved Core Length and Risk of Recurrence After Radical Prostatectomy
Article: Greatest Percentage Involved Core Length and Risk of Clinically Significant Prostate-Specific Antigen Failure After Radical Prostatectomy. Author: Anthony V. D’Amico Source: Clinical Genitourinary Cancer. March 5, 2015
New Prostate Cancer Immunotherapy- Prostvac
Dr. Barken introduces the New Prostate Cancer Immune Therapy for earlier stages of Prostate Cancer. Please watch the video below and see what he learned at the National Cancer Institute recent conference mentioned above. Dr. James Gulley explains the Prostvac … Continue reading
Posted in Clinical Trials, Immune Therapy, Prostate Cancer, PSA, Treatments for Prostate Cancer
Tagged PSA Only disease
Leave a comment
Enzalutamide and Prostvac for patients with PSA only disease after primary treatment
This very significant development could become the standard treatment for prostate cancer in the future. Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer. NIH Study- Recruiting- ClinicalTrials.gov Identifier: NCT01875250
Delaying Androgen Deprivation
Delaying Androgen Deprivation Therapy May not compromise Survival in Men with Prostate cancer and PSA-Only Relapse.
Active Surveillance- Canadian Experience Part 2.
Active Surveillance: Current status and future direction. Part 2. Mayo Clinic Review, Hawaii Feb 2 2014 Produced by UroToday. Click here to send me a question by sending a video. Click to view instructions.
PSA Response to Neoadjuvant Androgen Deprivation Therapy iIs a Strong Predictor of Survival
PSA Response to Neoadjuvant Androgen Deprivation Therapy Is a Strong Independent Predictor of Survival in High-Risk Prostate Cancer in the Dose-Escalated Radiation Therapy Era
RISING PSA AND THE USE OF PROSCAR
For the Ask Dr Barken Call In Show on Tuesday, Jan. 8th at 6pm Pacific- Dial 1-877-727-3301 to hear the program and speak with Dr. Barken. You may leave a question before the show by dialing the same number and recording … Continue reading